My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.73 +0.04 (+0.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, WOW, TRML, BTBD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paramount Group, Inc. (NYSE – PGRE), Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW)
From Brodsky & Smith LLC
Via GlobeNewswire
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRML, WOW, BTBD, WKHS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW), Workhorse Group Inc. (Nasdaq - WKHS)
From Brodsky & Smith LLC
Via GlobeNewswire
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
From The Ademi Firm
Via Business Wire
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
From Tourmaline Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.